234 related articles for article (PubMed ID: 31096782)
1. Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?
Hernández Martínez A; Pereira Delgado E; Silva Silva G; Castellanos Mateos L; Lorente Pascual J; Lainez Villa J; García Vicente P; Almeida-González CV
Eur J Ophthalmol; 2020 Sep; 30(5):1091-1098. PubMed ID: 31096782
[TBL] [Abstract][Full Text] [Related]
2. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch.
Ruiz-Medrano J; Rodríguez-Leor R; Almazán E; Lugo F; Casado-Lopez E; Arias L; Ruiz-Moreno JM
Eur J Ophthalmol; 2021 May; 31(3):1135-1145. PubMed ID: 32493065
[TBL] [Abstract][Full Text] [Related]
3. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
5. PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA.
Shah SU; Harless A; Bleau L; Maturi RK
Retina; 2016 Oct; 36(10):1986-96. PubMed ID: 27124881
[TBL] [Abstract][Full Text] [Related]
6. Analysis of anatomical biomarkers in subtypes of diabetic macular edema refractory to anti-vascular endothelial growth factor treated with dexamethasone implant.
Castro-Navarro V; Cervera-Taulet E; Navarro-Palop C; Hernández-Bel L; Monferrer-Adsuara C; Mata-Moret L; Montero-Hernández J
Eur J Ophthalmol; 2020 Jul; 30(4):764-769. PubMed ID: 30832509
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
8. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
[TBL] [Abstract][Full Text] [Related]
9. Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
Maggio E; Sartore M; Attanasio M; Maraone G; Guerriero M; Polito A; Pertile G
Am J Ophthalmol; 2018 Nov; 195():209-222. PubMed ID: 30098350
[TBL] [Abstract][Full Text] [Related]
10. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA.
Zhioua I; Semoun O; Lalloum F; Souied EH
Retina; 2015 Jul; 35(7):1429-35. PubMed ID: 26102440
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
[TBL] [Abstract][Full Text] [Related]
12. Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response.
Demir G; Ozkaya A; Yuksel E; Erdogan G; Tunc U; Celal Ocal M; Sakır Goker Y
Clin Drug Investig; 2020 Feb; 40(2):119-128. PubMed ID: 31768784
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
He Y; Ren XJ; Hu BJ; Lam WC; Li XR
BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.
Moon SY; Cho KH; Woo SJ; Park SP; Kim YK
Korean J Ophthalmol; 2018 Feb; 32(1):29-37. PubMed ID: 29376223
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab.
Joe AW; Wickremasinghe SS; Gillies MC; Nguyen V; Lim LL; Mehta H; Fraser-Bell S
Clin Exp Ophthalmol; 2019 Mar; 47(2):287-289. PubMed ID: 30084193
[No Abstract] [Full Text] [Related]
16. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
Shin YU; Hong EH; Lim HW; Kang MH; Seong M; Cho H
BMC Ophthalmol; 2017 Oct; 17(1):182. PubMed ID: 28974211
[TBL] [Abstract][Full Text] [Related]
17. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
Kim M; Cho YJ; Lee CH; Lee SC
Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
